Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Packham, David
EAGLE, NCT03749447 / 2018-003253-24: An Extended Access Program for Bardoxolone Methyl in Patients With CKD	Terminated	3	270	Europe, Japan, US, RoW	Bardoxolone methyl, RTA 402	Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc.	Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney	08/23	08/23
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -	Terminated	3	667	Europe, Japan, US, RoW	Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule	Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC	Autosomal Dominant Polycystic Kidney, ADPKD	08/23	08/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy	Active, not recruiting	3	380	Europe, Canada, Japan, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo	Chinook Therapeutics U.S., Inc.	IgA Nephropathy, Immunoglobulin A Nephropathy	09/23	12/26
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases	Active, not recruiting	2	103	Europe, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627	Chinook Therapeutics U.S., Inc.	IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy	07/24	07/26